In a previous study, we incorporated decitabine into the HAAG priming regimen (homoharringtonine, aclarubicin, low-dose cytarabine, and G-CSF) in patients with refractory/relapsed AML, and achieved an overall response rate (ORR) of 83% and complete remission (CR) rate of 58% (14). Here, CSF3 is linked to acute myeloid leukemia.